Cocrystal Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $13.05M
- P/E (TTM)
- –
- Dividend yield
- –
About Cocrystal Pharma
Pharmaceutical Preparations, SIC 2834
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics targeting serious and chronic viral infections. The company applies a proprietary structure-based drug discovery platform combining computational chemistry, medicinal chemistry, X-ray crystallography, and enzymology to design direct-acting small molecule antivirals. Its research and development programs focus on RNA viruses, specifically developing product candidates for influenza, norovirus, coronaviruses, and hepatitis C.
The company operates as a single business entity with corporate headquarters located in Bothell, Washington. Clinical-stage trials and research activities for its antiviral drug candidates take place across multiple international locations, including completed and ongoing clinical studies in the United States, Australia, the United Kingdom, and Canada.
Summary of the business section of Cocrystal Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cocrystal Pharma, Inc.
- Headquarters
- Bothell, WA
- Address
- 19805 N. Creek Parkway 98011
- Phone
- (786) 459-1831
- Website
- www.cocrystalpharma.com
- Employees
- 10, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weinberg & Company, P.A, Los Angeles, California
Stock & identifiers
- Ticker
- COCP
- Exchange
- Nasdaq
- Shares outstanding
- 19M, Aug 13, 2026
- Public float
- $11.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Aug 14, 2023; 1-for-12 reverse, Oct 11, 2022; 1-for-30 reverse, Mar 21, 2018; 1-for-30 reverse, Jan 24, 2018; 100-for-1, Aug 14, 2014
- SEC CIK
- 1412486
- CUSIP
- 19188J409
- ISIN
- US19188J4094
- LEI
- 549300QCJ6RBUJKI7S66
- EIN
- 35-2528215
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James Sapirstein | Chief Executive Officer | – |
| James Joseph Martin | Co-CEO and CFO | 44,167 |
| Sam Lee | President and Co-CEO | 76,355 |
| Carol L. Brosgart | Director | – |
| Phillip Md Et Al Frost | Director | 2,020,651 |
| Anthony J. Japour | Director | 14,924 |
| Fred Hassan | Director | 1,383,009 |
| Richard C. Pfenniger Jr | Director | 31,400 |
| Roger D. Kornberg | Director | 67,878 |
| Steven D. Rubin | Director | 7,206,235 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | – | $513.68K | – | $95 | – |
| FY2025 James Martin | $265.00K | $265.01K | – | $95 | – |
| FY2025 Principal Executive Officers | $513.67K | – | – | $95 | – |
| FY2025 Sam Lee | $248.67K | $248.67K | – | $95 | – |
| FY2024 | – | $1.22M | – | $110 | – |
| FY2024 James Martin | $680.86K | $610.46K | – | $110 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we employed 10 full-time employees.”
Corporate history
Events identified from SEC filings